LUGANO, SWITZERLAND — June 21, 2002 —
Treatment with a VAPEC-B chemotherapy regimen prior to limited field radiotherapy may significantly reduce the incidence of progression in patients with early stage, low risk Hodgkin’s disease.
Dr. John Radford from the Manchester Lymphoma Group, Christie Hospital in Manchester, United Kingdom presented the data here last week at the 8th International Conference on Malignant Lymphoma (ICML). Dr. Radford and his team randomly assigned 125 patients with low risk Hodgkin’s disease to treatment with radiotherapy alone (RT) or combination therapy (CT) between August 1989 and February 1997.
They treated the CT group with a four-week regimen of VAPEC-B followed by radiotherapy. The VAPEC-B regimen consisted of doxorubicin 35 mg/m² intravenously (IV) on weeks 1 and 3, cyclophosphamide 350 mg/m² IV on week 1, etoposide 100 mg/m² orally each day for five days on week 3, vincristine 1.4 mg/m² IV and bleomycin 10,000 IU/m² iv on weeks 2 and 4 with prednisone 50 mg daily for 4 weeks, and prophylactic co-trimoxazole and ketoconazole.
The eligibility criteria for the trial were clinical stages Ia/IIa Hodgkin’s disease, no B symptoms or mediastinal bulk, no previous treatment, and age less than 75 years. Patient characteristics such as stage, histological subtype, and the number of nodal sites at outset were well balanced between the two arms.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!